Q3 FY26 Investor Presentation
Filed with ASX · · 20 pages · English
In the deck
Story so far
Earlier from Orthocell
- First Surgical Use of Remplir in US Department of Defense
- Orthocell Secures Approval to sell Remplir™ to the U.S. Department of Defence Hospital Network
- OCC Secures Access to 221 U.S. Military Medical Centres
- Remplir Used in 23 Surgeries in Ukrainian soldiers
- Orthocell Appoints UK Distributor for Remplir
Later from Orthocell
- Compelling 90% Success Rate for Remplir in Real World Study
- First Sales of Remplir Achieved in US$75m Canadian Market
- Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine
- Orthocell Appoints Thailand Distributor for Remplir
- Q4 FY26 ASX Investor Presentation
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell